Eur Rev Med Pharmacol Sci 2019; 23 (10): 4293-4302

DOI: 10.26355/eurrev_201905_17934

A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

U. Basile, F. Gulli, M.A. Isgrò, C. Napodano, K. Pocino, S.A. Santini, L. Gragnani, L. Conti, E. Rossi, I. Cordone, A.L. Zignego, G.L. Rapaccini, G. Cigliana, F. Berruti, L. Todi, M. Marino, E. Di Stasio

Area Diagnostica di Laboratorio, UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy. mariapaola.marino@unicatt.it


OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways.
PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin’s lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS).
RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): in one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL.
CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.

Free PDF Download

To cite this article

U. Basile, F. Gulli, M.A. Isgrò, C. Napodano, K. Pocino, S.A. Santini, L. Gragnani, L. Conti, E. Rossi, I. Cordone, A.L. Zignego, G.L. Rapaccini, G. Cigliana, F. Berruti, L. Todi, M. Marino, E. Di Stasio
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 10
Pages: 4293-4302
DOI: 10.26355/eurrev_201905_17934